Company intelligence / Profile preview

Alleanza Pharmaceuticals, Inc.

Unknown, Unknown, United States?bmsscience.com ↗

Ownership: Private
Development stage: Preclinical

Overview

A pilot, single-masked Phase 2 study evaluated ALZ-1101 (Latanoprost/Dorzolamide ophthalmic solution) for safety and efficacy in patients with primary open angle glaucoma or ocular hypertension inadequately controlled by latanoprost alone. The study was completed; further details on results are not publicly available.

Therapeutic areas: Ophthalmology
Modalities: Small molecules (e.g., Dorzolamide/Latanoprost combination)
Industry: Biotech

Drug pipeline

1 asset

anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin

Pre-clinical

Indications: COVID-19

Beyond the preview

Go deeper on Alleanza Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alleanza Pharmaceuticals, Inc..

Explore the full profile